World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
83
Citations
25097
World Ranking
3491
National Ranking
1753

Medicine

D-Index
85
Citations
25476
World Ranking
14651
National Ranking
7414

Overview

Don L. Gibbons is affiliated with The University of Texas MD Anderson Cancer Center in the United States and has an extensive body of research focused primarily on medicine, with a significant emphasis on oncology and related biomedical fields. Their published works demonstrate a multidisciplinary approach covering biochemistry, genetics, molecular biology, pulmonary and respiratory medicine, and immunology.

The scientist's research spans multiple subfields including oncology, pulmonary and respiratory medicine, molecular biology, immunology, and cancer research. The main topics addressed relate deeply to cancer immunotherapy and biomarkers, lung cancer treatments and mutations, cancer genomics and diagnostics, as well as lung cancer diagnosis and treatment. Additional areas of focus include lung cancer research studies, radiomics and machine learning in medical imaging, and immune responses relevant to immunotherapy.

Frequent publication venues for Don L. Gibbons include:

  • Cancer Research
  • Journal of Thoracic Oncology
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • Nature Communications

Among notable recent papers by Don L. Gibbons are:

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021, Nature Medicine
  • Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion, 2020, Nature Communications
  • The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1, 2021, Cancer Cell
  • Deep learning-based prediction of the T cell receptor-antigen binding specificity, 2021, Nature Machine Intelligence
  • Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer, 2021, Journal for ImmunoTherapy of Cancer

Don L. Gibbons has collaborated extensively with several frequent co-authors, including John V. Heymach, Jianjun Zhang, Tina Cascone, Ignacio I. Wistuba, and J. Jack Lee. These collaborations reflect a strong network within cancer research and clinical oncology communities.

Best Publications

  • Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

    Daniel R. Gomez;Chad Tang;Jianjun Zhang;George R. Blumenschein

  • Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study

    Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez

  • Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

    Limo Chen;Don Lynn Gibbons;Sangeeta Goswami;Maria Angelica Abdalla Cortez

  • Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer

    Triparna Sen;B. Leticia Rodriguez;Limo Chen;Carminia Della Corte

  • Clinical trials for stem cell therapies.

    Alan Trounson;Rahul G Thakar;Geoff Lomax;Don Gibbons

  • Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.

    Tina Cascone;William N. William;Annikka Weissferdt;Cheuk H. Leung

  • Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

    Don L. Gibbons;Wei Lin;Chad J. Creighton;Zain H. Rizvi

  • Treatment of non-small-cell lung cancer with erlotinib or gefitinib.

    Vince D. Cataldo;Don Lynn Gibbons;Román Pérez-Soler;Alfonso Quintás-Cardama

  • Epithelial–Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma

    Yanyan Lou;Lixia Diao;Edwin Roger Parra Cuentas;Warren L. Denning

  • Conformational change and protein-protein interactions of the fusion protein of Semliki Forest virus.

    Don L. Gibbons;Don L. Gibbons;Marie Christine Vaney;Alain Roussel;Armelle Vigouroux

  • A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition.

    Milena P. Mak;Milena P. Mak;Pan Tong;Lixia Diao;Robert J. Cardnell

  • CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-l1 blockade

    Limo Chen;Lixia Diao;Yongbin Yang;Xiaohui Yi

  • Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion.

    David H. Peng;Bertha Leticia Rodriguez;Lixia Diao;Limo Chen

  • Smoking, p53 Mutation, and Lung Cancer

    Don Lynn Gibbons;Lauren Averett Byers;Jonathan M Kurie

  • Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues.

    Edwin R. Parra;Naohiro Uraoka;Mei Jiang;Pamela Cook

  • miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1

    Jonathon D. Roybal;Yi Zang;Young Ho Ahn;Yanan Yang

  • The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200–dependent pathway in mice

    Yanan Yang;Young Ho Ahn;Don L. Gibbons;Yi Zang

  • The fibrotic tumor stroma

    Mitsuo Yamauchi;Thomas H. Barker;Don L. Gibbons;Jonathan M. Kurie

  • TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence.

    Alexandre Reuben;Rachel Gittelman;Jianjun Gao;Jiexin Zhang

  • Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.

    C. Allison Stewart;Pan Tong;Robert J. Cardnell;Triparna Sen

Frequent Co-Authors

John V. Heymach
John V. Heymach The University of Texas MD Anderson Cancer Center
Ignacio I. Wistuba
Ignacio I. Wistuba The University of Texas MD Anderson Cancer Center
Carmen Behrens
Carmen Behrens The University of Texas MD Anderson Cancer Center
Jing Wang
Jing Wang The University of Texas MD Anderson Cancer Center
Lixia Diao
Lixia Diao The University of Texas MD Anderson Cancer Center
Chad J. Creighton
Chad J. Creighton Baylor College of Medicine
Jonathan M. Kurie
Jonathan M. Kurie The University of Texas MD Anderson Cancer Center
Stephen G. Swisher
Stephen G. Swisher The University of Texas MD Anderson Cancer Center
J. Jack Lee
J. Jack Lee The University of Texas MD Anderson Cancer Center
Chantale Bernatchez
Chantale Bernatchez The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring advanced careers beyond undergraduate studies in Biology or Biochemistry, a range of online degrees are available to help you specialize and expand your expertise. Many students pursue fields related to healthcare administration, pharmacy, or advanced clinical practice.

Those interested in leadership can consider the number of cahme accredited mha programs that offer quality education in healthcare management through flexible online study. For clinical roles, exploring the best online dnp programs—some of which do not require on-campus clinical hours—can be an excellent next step for nurses aiming for the highest levels of practice.

If you are interested in management and research, pursuing a phd in healthcare administration online may be ideal for building skills in policy, leadership, or organizational change. Students considering pharmaceutical sciences can advance their training with an online pharmd, preparing for critical roles in research, clinical pharmacy, or drug development.

These degree pathways can open doors to specialized, high-impact careers while offering the flexibility needed by today’s students and professionals.

Best Scientists Citing Don L. Gibbons

Trending Scientists